JP Morgan Chase
HUMA icon

JP Morgan Chase’s Humacyte HUMA Stock Holding History

JP Morgan Chase’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Sell
13,590
-67,342
-83% -$62.4K ﹤0.01% 6897
2026
Q1 		$46.5K Buy
80,932
+5,150
+7% +$5.35K ﹤0.01% 6235
2025
Q4 		$72.8K Buy
75,782
+11,620
+18% +$16.5K ﹤0.01% 6066
2025
Q3 		$112K Sell
64,162
-5,905
-8% -$11.6K ﹤0.01% 5840
2025
Q2 		$146K Buy
70,067
+16,702
+31% +$32.1K ﹤0.01% 5417
2025
Q1 		$91K Buy
53,365
+2,721
+5% +$10.2K ﹤0.01% 5617
2024
Q4 		$256K Sell
50,644
-1,191
-2% -$5.89K ﹤0.01% 5370
2024
Q3 		$282K Sell
51,835
-356
-0.7% -$2.35K ﹤0.01% 5239
2024
Q2 		$251K Buy
52,191
+4,360
+9% +$22.7K ﹤0.01% 5041
2024
Q1 		$149K Sell
47,831
-14,141
-23% -$47.6K ﹤0.01% 5498
2023
Q4 		$176K Buy
61,972
+377
+0.6% +$968 ﹤0.01% 5461
2023
Q3 		$180K Buy
61,595
+8,069
+15% +$26.7K ﹤0.01% 5125
2023
Q2 		$153K Buy
53,526
+2,548
+5% +$9.19K ﹤0.01% 5242
2023
Q1 		$157K Buy
50,978
+13,676
+37% +$38.9K ﹤0.01% 5201
2022
Q4 		$79K Buy
37,302
+19,784
+113% +$60.1K ﹤0.01% 5442
2022
Q3 		$58K Buy
17,518
+2,932
+20% +$11.2K ﹤0.01% 5496
2022
Q2 		$47K Buy
14,586
+2,034
+16% +$11.3K ﹤0.01% 5677
2022
Q1 		$89K Sell
12,552
-1,846
-13% -$10.7K ﹤0.01% 5563
2021
Q4 		$105K Buy
+14,398
New +$142K ﹤0.01% 5658

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's HUMA Position: Q2 2026 in Review

JP Morgan Chase reduced its Humacyte (HUMA) stake by 83% in Q2 2026, selling an estimated $62.4K and leaving 13,590 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6897.

JP Morgan Chase first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $282K in Q3 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • JP Morgan Chase held 13,590 shares of Humacyte worth $10.9K as of Q2 2026.
  • JP Morgan Chase sold 67,342 Humacyte shares in Q2 2026, an estimated $62.4K.
  • Humacyte made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6897 holding.
  • JP Morgan Chase first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's Humacyte position peaked at $282K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.